万邦医药(301520.SZ)发布前三季度业绩，归母净利润3311.06万元，下降57.44%

Core Viewpoint - Wanbang Medical (301520.SZ) reported a significant decline in revenue and net profit for the first three quarters of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company's revenue for the first three quarters was 209 million yuan, a year-on-year decrease of 28.60% [1] - The net profit attributable to shareholders was 33.11 million yuan, down 57.44% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 8.45 million yuan, a decrease of 84.89% year-on-year [1] - Basic earnings per share were 0.50 yuan [1]